Pamela Esposito has 25 years of strategy, business, and corporate development experience in small biotech companies, playing lead roles in transformative deals for each organization. Pamela was most recently Chief Business Officer of Replimune, a position she held for 9 years from company inception. Previously, she was Chief Business Officer at Ra Pharmaceuticals where she played a leadership role in strategy, helping Ra transform from a discovery platform to a clinical stage company. Prior to Ra, she was VP of Business Development at Biovex and led the negotiation of the acquisition of the company by Amgen. Over her career, she has been responsible for raising over $1B in capital and putting high-value, creative partnerships in place. In addition to serving on Accent’s board of directors, Pamela sits on the board of directors of Kymera Therapeutics and Sapience Therapeutics. Pamela earned a PhD in pharmacology from Tufts University School of Medicine and a BA from Dartmouth College.